NCT02235961

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise healthy male subjects.

Conditions

• Metabolism and Nutrition Disorder
• Obesity

Interventions

Type	Name	Description
DRUG	NNC9204-0530	Administered as single subcutaneous (s.c., under the skin) injections.
DRUG	liraglutide	Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
DRUG	placebo	Administered as single subcutaneous (s.c., under the skin) injections.

Timeline

• Start date: 2014-09-04
• Primary completion: 2016-07-06
• Completion: 2016-07-06
• First posted: 2014-09-10
• Last updated: 2017-07-27

Locations

1 site across 1 country: United States